Botanical species · safety record

Argyreia nervosa

The EFSA Compendium of Botanicals holds 19 constituent measurements and 2 adverse-effect records for Argyreia nervosa. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Argyreia nervosa (Burm.f.) Bojer

19Constituent measurements
2Safety records
8Cited sources
0Licensed products (Canada)

Also recorded as

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Lysergic acid5
  • Ergine3
  • Ergometrine3
  • Chanoclavine-12
  • Coumarins1
  • Elymoclavine1
  • Ergot alkaloids1
  • Lysergol1
  • Phenylpropanoids1
  • Scopoletin1

Plant parts

  • Seed17
  • Roots and other underground parts2
  • Unspecified1

Preparations

  • Solvent extraction14

Effect types

  • Musclo-skeletal1
  • Neurotoxicity1

Target tissues

  • Heart1
  • Neurologic1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
Chanoclavine-1Seed3.62 PercentResolve DOI
Chanoclavine-1SeedSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
CoumarinsRoots and other underground partsSolvent extractionPhytochemical screeningResolve DOI
ElymoclavineSeedResolve DOI
ErgineSeedSolvent extraction780 Microgram/gramStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
ErgineSeedSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
ErgineSeedSolvent extraction555 Microgram/gramStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
ErgometrineSeedSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
ErgometrineSeedResolve DOI
ErgometrineSeedSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
Ergot alkaloidsSeedSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
Lysergic acidSeedSolvent extraction≥ 1.73 Microgram/0,01 gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
Lysergic acidSeed8.2 PercentResolve DOI
Lysergic acidSeedSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
LysergolSeedSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
PhenylpropanoidsRoots and other underground partsSolvent extractionPhytochemical screeningResolve DOI
Lysergic acidSeedSolvent extraction0.04 PercentStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
Lysergic acidSeedSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
ScopoletinUnspecifiedNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
Musclo-skeletalHeartSeedHuman (as organism)Study with volunteersResolve DOI
NeurotoxicityNeurologicAcute toxicityNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Galani, Varsha J., Patel, Bharatkumar G. Psychotropic activity of Argyreia speciosa roots in experimental animals. . Ayu, 2011, vol. 32, no. 3, p. 380-4. DOI
  2. MILLER, MD. ISOLATION AND IDENTIFICATION OF LYSERGIC ACID AMIDE AND ISOLYSERGIC ACID AMIDE AS PRINCIPAL ERGOLINE ALKALOIDS IN ARGYREIA-NERVOSA, A TROPICAL WOOD ROSE . Journal of the association of official analytical chemists, 1970, vol. 53, no. 1, p. 123-&.
  3. Kremer, Christian., Paulke, Alexander., Wunder, Cora., Toennes, Stefan W. Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds . Forensic science international, 2012, vol. 214, no. 1-3, p. E6-E8. DOI
  4. Borsutzky, M., Passie, T., Paetzold, W., Emrich, HM., Schneider, U. Hawaiian baby woodrose: (Psycho-) pharmacological effects of the seeds of Argyreia nervosa. A case-orientated demonstration . Nervenarzt, 2002, vol. 73, no. 9, p. 892-896. DOI
  5. Paulke, Alexander., Kremer, Christian., Wunder, Cora., Wurglics, Mario., Schubert-Zsilavecz, Manfred., Toennes, Stefan W. Studies on the alkaloid composition of the Hawaiian Baby Woodrose Argyreia nervosa, a common legal high . Forensic science international, 2015, vol. 249, p. 281-293. DOI
  6. Srivastava, A., Shukla, YN. Aryl esters and a coumarin from Aygyreia speciosa. Indian journal of chemistry section b-organic chemistry including medicinal chemistry, 1998, vol. 37, no. 2, p. 192-194.
  7. HYLIN, JW., WATSON, DP. ERGOLINE ALKALOIDS IN TROPICAL WOOD ROSES. Science, 1965, vol. 148, no. 3669, p. 499-&. DOI
  8. Simonienko, K., Waszkiewicz, N., Szulc, A. Psychoactive plant species - Actual list of plants prohibited in Poland Roslinne srodki odurzajace - Aktualnie obowiazujaca lista w Polsce . Psychiatria polska, 2013, vol. 47, no. 3, p. 499-510.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue